… Initial phase II trials of erlotinib and gefitinib in the firstline setting demonstrated at best
modest efficacy in unselected patients, with rather disappointing response rates (4–23%), PFS (…

… Randomized trials of advanced non-small cell lung cancer (NSCLC) have demonstrated
the activity of docetaxel in second-line and erlotinib in the third-line setting after failure of …

… in the Asian population, never-smokers, women, and patients with adenocarcinoma led
to the first phase 3 trial comparing an EGFR TKI with chemotherapy in the first-line setting. …

… were on first-line gefitinib, erlotinib or afatinib, respectively. Patients treated with afatinib in
the first-line setting had significantly longer OS compared with those on gefitinib or erlotinib, …

… -TKI), such as erlotinib or gefitinib, demonstrated efficacy in … -TKIs, including erlotinib, gefitinib
and afatinib are effective in … -TKIs in the front-line setting, focusing on the role of erlotinib. …

… with erlotinib [11]. Afatinib and gefitinib have also demonstrated efficacy in the first-line …
A sample size of 139 events was calculated to provide 85% power (significant P value set at …

… Given the efficacy of EGFR TKI therapy in previously treated patients, many groups have
explored the use of erlotinib and gefitinib in the firstline setting. In the ensuing sections, …

… Without adjustment by gender, smoking history, and cell type, the … patients according to
different lines of gefitinib or erlotinib. The disparities of choices on gefitinib or erlotinib (more male…

… (PD-1), is an effective first- and second-line treatment option for patients with advanced
NSCLC.1, … and response rate and time to progression after treatment with gefitinib or erlotinib.3, 4 …

… erlotinib or gefitinib as first-line therapy are summarized in Table 1 . As a result of these studies
of TKIs in the first-line setting … the label of erlotinib to include first-line therapy for patients …